New Brunswick Scientific Co., Inc. Names Dr. Arthur Blume CEO of DGI BioTechologiesNew Brunswick Scientific Co., Inc.
...DR. ARTHUR BLUME CEO OF DGI BIOTECHNOLOGIES Edison, New Jersey, February 7, 2000 -- New Brunswick Scientific Co., Inc. (NBS) (Nasdaq:NBSC), today announced that Arthur J. Blume, Ph.D., has been appointed to the additional position of chief executive officer of the Company's majority-owned DGI BioTechnologies LLC.Dr. Blume also serves as DGI's president and chief operating officer. Dr. Blume, 58, founded DGI in 1995 and is the developer of its proprietary Diogenesis® drug-lead-discovery process.He
has more than 25 years of research and drug-discovery experience, including his
tenure as chief operating officer of GeneLogic, Inc.
, and previous senior-level positions with Lederle Laboratories and the Roche Institute of Molecular Biology
.From 1967 to 1971, Blume was a staff and post doctorate fellow with the National Institutes of Health, where he established and characterized the first neuronal tissue cultures.Dr. Blume earned his M.S. and Ph.D., Bacterial Genetics and Molecular Biology, (1963-68) from Syracuse University.
Said Dr. Blume
: "This is an exciting time for DGI
, which is anticipating an expansion this year of its collaborative effort with research partner Novo Nordisk.We have an excellent core scientific team in place, and we intend to develop that infrastructure as DGI
continues to grow its intellectual property portfolio, accelerate and expand the number and scope of projects on which we are working, and seek additional strategic partners to enhance our development." He
continued: "Another key initiative this year is aimed at improving our visibility in the scientific and financial communities via a more proactive communication program.